Omnicell (OMCL) Stock Price, News & Analysis

Company Overview

Omnicell, Inc. develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations. Omnicell also offers services and cloud-based technologies intended to connect medication management activities across hospitals, pharmacies, ambulatory settings and patients’ homes.

Founded in 1992 and headquartered in Mountain View, California, Omnicell serves customers primarily in the United States and also operates internationally, including in markets such as Canada, the United Kingdom and Australia. The company was founded by Randall Lipps, who has remained a prominent leader and serves as its executive chairman.

Key Stats

• Today's Range: $36.75 to $37.83
• 50-Day Range: $32.23 to $37.75
• 52-Week Range: $29.09 to $55.00
• Volume: 539,723 shs
• Average Volume: 475,878 shs
• Market Capitalization: $1.68 billion
• P/E Ratio: 24.51
• Dividend Yield: N/A
• Price Target: $57.86
• Consensus Rating: Moderate Buy

Omnicell Stock Analysis - MarketRank™

Omnicell scored higher than 73% of companies evaluated by MarketBeat, and ranked 489th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Omnicell has a consensus price target of $57.86, representing about 56.5% upside from its current price of $36.97.

Amount of Analyst Coverage

Omnicell has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: -26.95%

Earnings Growth

Earnings for Omnicell are expected to decrease by -26.95% in the coming year, from $1.41 to $1.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omnicell is 24.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.13.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omnicell is 24.51, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.99.

Price to Earnings Growth Ratio

Omnicell has a PEG Ratio of 0.95. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Omnicell has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.40% of the float of Omnicell has been sold short.

Short Interest Ratio / Days to Cover

Omnicell has a short interest ratio ("days to cover") of 7.48.

Change versus previous month

Short interest in Omnicell has recently decreased by 10.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omnicell does not currently pay a dividend.

Dividend Growth

Omnicell does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Omnicell this week, compared to 4 articles on an average week.

MarketBeat Follows

7 people have added Omnicell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omnicell insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.92% of the stock of Omnicell is held by insiders.

Percentage Held by Institutions

97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:OMCL
• CIK: 926326
• Web: www.omnicell.com
• Phone: (877) 415-9990
• Fax: 847-596-3402
• Employees: 3,580
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Omnicell: $57.86
• High Price Target: $70.00
• Low Price Target: $45.00
• Potential Upside/Downside: +56.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.84
• Trailing P/E Ratio: 24.51
• Forward P/E Ratio: 26.22
• P/E Growth: 0.95
• Net Income: $2.05 million
• Net Margins: 3.13%
• Pretax Margin: 4.90%
• Return on Equity: 5.66%
• Return on Assets: 3.57%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.64
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $1.18 billion
• Price / Sales: 1.42
• Cash Flow: $2.71 per share
• Price / Cash Flow: 13.65
• Book Value: $27.45 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 45,480,000
• Free Float: 44,151,000
• Market Cap: $1.68 billion
• Optionable: Optionable
• Beta: 0.98